English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

of results Of 139 patients, 81 were on Truvada and 58 on Kivexa. Most were black African (69%), mean age 38.1 (+/8.1) years and 50.3% were female. Mean baseline VL was 5.4 (+/5.6) log10 copies/ml and CD4 count 172 (+/84) cells/mm3 of blood. One patient in the Truvada arm and one in the Kivexa discontinued for possible side-effects. Patients on Kivexa were HLA-B* 5701 negative. At 48 weeks, on intention-to-treat analysis, VL suppression below 400 copies/ml in Truvada and Kivexa arms were 93.5% and 96.2% (p = 0.1) and below 40 copies in 83.3% and 85.1% (p = 0.6), respectively. Mean rise in CD4 count was similar in both groups. Results were not predicted by baseline VL. Increase in serum total cholesterol (TC) was higher in Kivexa (p = 0.04), but triglycerides (TG), HDLcholesterol (HDL), TC/HDL and e-GFR were not different (Table 1).

The TOKEN study: safety and efficacy of Truvada or Kivexa in combination with efavirenz in treatment-naïve predominantly black African HIV patients